Marsal Therapeutics Inc. has described compounds reported to be useful for the treatment of glioblastoma multiforme (GBM).

Morphic Therapeutic Inc. has divulged integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of inflammatory bowel disease (IBD).

Gilead Sciences Inc. has identified nucleoside prodrugs reported to be useful for the treatment of viral infections.

Impact Therapeutics Inc. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of neurologic cancer.

Newave Pharmaceutical LLC has disclosed GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.

National Science & Technology Development Agency (NSTDA) has described cordycepin derivatives acting as viral replication inhibitors reported to be useful for the treatment of viral infections.

Scientists at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged prop-2-ynamide derivatives acting as EGFR (Exon 20 insertion [Ex20Ins] mutant) inhibitors reported to be useful for the treatment of cancer, in particular non-small-cell lung cancer (NSCLC).

Insilico Medicine Ltd. has identified postsynaptic density-95 (PSD-95) protein inhibitors acting as neuroprotective agents reported to be useful for the treatment of epilepsy, anxiety disorders, neurodegeneration, neuropathic pain, stroke and cerebral infarction.

Shanghai Helioson Pharmaceutical Co. Ltd. has synthesized molecular glue degraders comprising an E3 ubiquitin ligase coupled to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) targeting moiety acting as GSPT1 degradation inducers reported to be useful for the treatment of cancer.

Gilead Sciences Inc. has disclosed GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.